

## Originalarbeiten

**Flegar L.**, Groeben C., Koch R. et al. Trends in Renal Tumor Surgery in the United States and Germany Between 2006 and 2014: Organ Preservation Rate Is Improving. *Ann Surg Oncol* (2019). <https://doi.org/10.1245/s10434-019-08108-x> *IF 5.344 (2020)*

**Flegar L.**, et al. Vascular-targeted Photodynamic Therapy in Unilateral Low-risk Prostate Cancer in Germany: 2-yr Single-centre Experience in a Real-world Setting Compared with Radical Prostatectomy. *Eur Urol Focus* (2021), <https://doi.org/10.1016/j.euf.2021.01.018c> *IF 5.996 (2020)*

Groeben C, Koch R, Baunacke M, **Flegar L**, Borkowetz A, Thomas C, Huber J. Entwicklung der operativen Uroonkologie in Deutschland – vergleichende Analysen aus populationsbasierten Daten [Trends in uro-oncological surgery in Germany-comparative analyses from population-based data]. *Urologe A*. 2021 Sep 6. German. doi: 10.1007/s00120-021-01623-4. Epub ahead of print. PMID: 34490495.

**Flegar L.**, Baunacke M., Buerk B.T., et al. Decision Regret and Quality of Life after Focal Therapy with Vascular-Targeted Photodynamic Therapy (TOOKAD) for Localized Prostate Cancer. *Urol Int.* (2021) doi: 10.1159/000520084 *IF 2.089 (2020)*

**Flegar L.**, Kraywinkel K, Zacharis A, Aksoy C, Koch R, Eisenmenger N, Groeben C, Huber J. Treatment trends for muscle-invasive bladder cancer in Germany from 2006 to 2019. *World J Urol.* 2022 Apr 29. doi: 10.1007/s00345-022-04017-z. Epub ahead of print. PMID: 35486177.

**Flegar L.**, Zacharis, A., Aksoy, C. et al. Alternative- and focal therapy trends for prostate cancer: a total population analysis of in-patient treatments in Germany from 2006 to 2019. *World J Urol* (2022). <https://doi.org/10.1007/s00345-022-04024-0>

Herout R, Baunacke M, **Flegar L**, et al. Upper tract urothelial carcinoma in Germany: epidemiological data and surgical treatment trends in a total population analysis from 2006 to 2019 [published online ahead of print, 2022 Nov 29]. *World J Urol.* 2022;10.1007/s00345-022-04219-5. doi:10.1007/s00345-022-04219-5

Leuchtweis I, Groeben C, **Flegar L**, et al. Ambulant vor stationär? – Versorgungswirklichkeit und ökonomische Analyse von kleinen urologischen Eingriffen in Deutschland von 2013 bis 2018 [Outpatient before inpatient treatment?-Reality of care and economic analysis for minor urological interventions in Germany between 2013 and 2018]. *Urologie.* 2022;61(11):1229-1236. doi:10.1007/s00120-022-01873-w

**Flegar L.**, Thoduka SG, Mahnken AH, Figiel J, Heers H, Aksoy C, Eisenmenger N, Groeben C, Huber J, Zacharis A. Focal Therapy for Renal Cancer: Comparative Trends in the USA and Germany from 2006 to 2020 and Analysis of the German Health Care Landscape. *Urol Int.* 2023 Jan 26:1-10. doi: 10.1159/000528559. Epub ahead of print. PMID: 36702105.

**Flegar L.**, Thoduka SG, Librizzi D et al. Adoption of Lutetium-177 PSMA radioligand therapy for metastatic castration resistant prostate cancer: a total population analysis in Germany from 2016 to 2020 – Angenommen in *European Journal of Nuclear Medicine and Molecular Imaging*

Kraywinkel K, **Flegar L.**, Huber J, Groeben C. Krebsregister in Deutschland: Was bringt die Zukunft für die Urologie? – Angenommen in *Aktuelle Urologie*